Article
Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch, T., Kuhn, S.A., Joedicke, A., Hanisch, U.K., Vajkoczy, P., Hoffmann, J. and Fichtner, I.
Journal of Cancer Research and Clinical Oncology 144
(5): 809-819.
May 2018
Loss-of-function uORF mutations in human malignancies.
Schulz, J., Mah, N., Neuenschwander, M., Kischka, T., Ratei, R., Schlag, P.M., Castaños-Vélez, E., Fichtner, I., Tunn, P.U., Denkert, C., Klaas, O., Berdel, W.E., von Kries, J.P., Makalowski, W., Andrade-Navarro, M.A., Leutz, A. and Wethmar, K.
Scientific Reports 8
(1): 2395.
5 February 2018
Animal models for personalized treatment options.
Fichtner, I., Klinghammer, K., Behrens, D., Flechsig, S., Rolff, J., Becker, M., Wulf-Goldenberg, A., Stecklum, M., Rivera, M., Brzezicha, B., Jandrig, B. and Hoffmann, J.
International Journal of Clinical Pharmacology and Therapeutics 55
(8): 698-700.
August 2017
Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.
Hendriks, H.R., Govaerts, A.S., Fichtner, I., Burtles, S., Westwell, A.D. and Peters, G.J.
British Journal of Cancer 117
(2): 195-202.
11 July 2017
SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival.
Schmid, F., Wang, Q., Huska, M.R., Andrade-Navarro, M.A., Lemm, M., Fichtner, I., Dahlmann, M., Kobelt, D., Walther, W., Smith, J., Schlag, P.M. and Stein, U.
Oncogene 35
(46): 5942-5952.
17 November 2016
Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes.
Orthmann, A., Peiker, L., Fichtner, I., Hoffmann, A., Hilger, R.A. and Zeisig, R.
Journal of Biomedical Nanotechnology 12
(1): 56-68.
January 2016
A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer, K., Raguse, J.D., Plath, T., Albers, A.E., Joehrens, K., Zakarneh, A., Brzezicha, B., Wulf-Goldenberg, A., Keilholz, U., Hoffmann, J. and Fichtner, I.
International Journal of Cancer 136
(12): 2940-2948.
15 June 2015
How perifosine affects liposome-encapsulated drug delivery across a cell barrier.
Testen, A, Podlipec, R, Mravljak, J, Orthmann, A, Sentjurc, M, Zeisig, R, Strancar, J and Koklic, T
Therapeutic Delivery 6
(4): 423-441.
April 2015
Cell differentiation mediated by co-culture of human umbilical cord blood stem cells with murine hepatic cells.
Stecklum, M., Wulf-Goldenberg, A., Purfürst, B., Siegert, A., Keil, M., Eckert, K. and Fichtner, I.
In Vitro Cellular & Developmental Biology Animal 51
(2): 183-191.
February 2015
Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
Vallespi, M.G., Pimentel, G., Cabrales-Rico, A., Garza, J., Oliva, B., Mendoza, O., Gomez, Y., Basaco, T., Sanchez, I., Calderon, C., Rodriguez, J.C., Markelova, M.R., Fichtner, I., Astrada, S., Bollati-Fogolín, M., Garay, H.E. and Reyes, O.
Journal of Peptide Science 20
(11): 850-859.
November 2014
In vitro and in vivo investigations into the carbene copper bromide anticancer drug candidate WBC4.
Walther, W., Fichtner, I., Hackenberg, F., Streciwilk, W. and Tacke, M.
Letters in Drug Design & Discovery 11
(7): 825-832.
August 2014
Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly.
Belz, K., Schoeneberger, H., Wehner, S., Weigert, A., Boenig, H., Klingebiel, T., Fichtner, I. and Fulda, S.
Blood 124
(2): 240-250.
10 July 2014
Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma.
Friesen, C., Hormann, I., Roscher, M., Fichtner, I., Alt, A., Hilger, R., Debatin, K.M. and Miltner, E.
Cell Cycle 13
(10): 1560-1570.
15 May 2014
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.
Redmer, T., Welte, Y., Behrens, D., Fichtner, I., Przybilla, D., Wruck, W., Yaspo, M.L., Lehrach, H., Schaefer, R. and Regenbrecht, C.R.A.
PLoS ONE 9
(5): e92596.
5 May 2014
Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.
Kobelt, D., Aumann, J., Schmidt, M., Wittig, B., Fichtner, I., Behrens, D., Lemm, M., Freundt, G., Schlag, P.M. and Walther, W.
Molecular Oncology 8
(3): 609-619.
May 2014
Combined Wnt/β-catenin, met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome.
Holland, J.D., Györffy, B., Vogel, R., Eckert, K., Valenti, G., Fang, L., Lohneis, P., Elezkurtaj, S., Ziebold, U. and Birchmeier, W.
Cell Reports 5
(5): 1214-1227.
12 December 2013
A seven-year storage report of good manufacturing practice-grade naked plasmid DNA: stability, topology, and in vitro/in vivo functional analysis.
Walther, W., Schmeer, M., Kobelt, D., Baier, R., Harder, A., Walhorn, V., Anselmetti, D., Aumann, J., Fichtner, I. and Schleef, M.
Human Gene Therapy Clinical Development 24
(4): 147-153.
December 2013
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Loeschmann, N., Michaelis, M., Rothweiler, F., Zehner, R., Cinatl, J., Voges, Y., Sharifi, M., Riecken, K., Meyer, J., von Deimling, A., Fichtner, I., Ghafourian, T., Westermann, F. and Cinatl Jr., J.
Translational Oncology 6
(6): 685-696.
December 2013
Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors.
Stachelscheid, H., Wulf-Goldenberg, A., Eckert, K., Jensen, J., Edsbagge, J., Bjoerquist, P., Rivero, M., Strehl, R., Jozefczuk, J., Prigione, A., Adjaye, J., Urbaniak, T., Bussmann, P., Zeilinger, K. and Gerlach, J.C.
Journal of Tissue Engineering and Regenerative Medicine 7
(9): 729-741.
September 2013
Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology.
Gries, J., Schumacher, D., Arand, J., Lutsik, P., Markelova, M.R., Fichtner, I., Walter, J., Sers, C. and Tierling, S.
Epigenetics 8
(7): 765-771.
July 2013
The activity of titanocene T against xenografted Caki-1 tumors.
Walther, W., Fichtner, I., Deally, A., Hogan, M. and Tacke, M.
Letters in Drug Design & Discovery 10
(5): 375-381.
June 2013
Cell death sensitization of leukemia cells by opioid receptor activation.
Friesen, C., Roscher, M., Hormann, I., Fichtner, I., Alt, A., Hilger, R.A., Debatin, K.M. and Miltner, E.
Oncotarget 4
(5): 677-690.
16 April 2013
Synergistic activity of bortezomib and HDACis in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT and NF-κB.
Bastian, L., Hof, J., Pfau, M., Fichtner, I., Eckert, C., Henze, G., Prada, J., von Stackelberg, A., Seeger, K. and Shalapour, S.
Clinical Cancer Research 19
(6): 1445-1457.
15 March 2013
Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz, F., Azab, S., Zeisig, R., Fichtner, I. and Warnecke, A.
International Journal of Pharmaceutics 441
(1-2): 499-506.
30 January 2013
In vitro and in vivo investigations into the carbene silver acetate anticancer drug candidate SBC1.
Fichtner, I., Cinatl, J., Michaelis, M., Sanders, L.C., Hilger, R., Kennedy, B.N., Reynolds, A.L., Hackenberg, F., Lally, G., Quinn, S.J., McRae, I. and Tacke, M.
Letters in Drug Design & Discovery 9
(9): 815-822.
November 2012
Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj, K., El-Abadla, N., Welker, P., Azab, S., Zeisig, R., Fichtner, I. and Kratz, F.
European Journal of Cancer 48
(13): 2054-2065.
September 2012
Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation.
Dahlmann, M., Sack, U., Herrmann, P., Lemm, M., Fichtner, I., Schlag, P.M. and Stein, U.
Oncotarget 3
(8): 783-797.
7 August 2012
Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
Kratz, F., Fichtner, I. and Graeser, R.
Investigational New Drugs 30
(4): 1743-1749.
August 2012
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
Abolhassani, M., Guais, A., Sanders, E., Campion, F., Fichtner, I., Bonte, J., Baronzio, G., Fiorentini, G., Israel, M. and Schwartz, L.
Investigational New Drugs 30
(4): 1331-1342.
August 2012
In vitro and in vivo studies into the biological activities of 1,10-phenanthroline, 1,10-phenanthroline-5,6-dione and its copper(II) and silver(I) complexes.
McCann, M., Santos, A.L.S., da Silva, B.A., Romanos, M.T.V., Pyrrho, A.S., Devereux, M., Kavanagh, K., Fichtner, I. and Kellett, A.
Toxicology Research 1
(1): 47-54.
July 2012
Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.
Orthmann, A., Zeisig, R., Suess, R., Lorenz, D., Lemm, M. and Fichtner, I.
Pharmaceutical Research 29
(7): 1949-1959.
July 2012
High prevalence and breast cancer predisposing role of the BLMc.1642 C>T (Q548X) mutation in Russia.
Sokolenko, A.P., Iyevleva, A.G., Preobrazhenskaya, E.V., Mitiushkina, N.V., Abysheva, S.N., Suspitsin, E.N., Kuligina, E.S., Gorodnova, T.V., Pfeifer, W., Togo, A.V., Turkevich, E.A., Ivantsov, A.O., Voskresenskiy, D.V., Dolmatov, G.D., Bit-Sava, E.M., Matsko, D.E., Semiglazov, V.F., Fichtner, I., Larionov, A.A., Kuznetsov, S.G., Antoniou, A.C. and Imyanitov, E.N.
International Journal of Cancer 130
(12): 2867-2873.
15 June 2012
Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors.
Walther, W., Petkov, S., Kuvardina, O.N., Aumann, J., Kobelt, D., Fichtner, I., Lemm, M., Piontek, J., Blasig, I.E., Stein, U. and Schlag, P.M.
Gene Therapy 19
(5): 494-503.
May 2012
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger, M., Schmitz, P., Zeisig, R., Naggi, A., Torri, G., Casu, B. and Bendas, G.
Thrombosis Research 129
(5): 603-610.
May 2012
Intrahepatic transplantation of CD34(+) cord blood stem cells into newborn and adult NOD/SCID mice induce differential organ engraftment.
Wulf-Goldenberg, A., Keil, M., Fichtner, I. and Eckert, K.
Tissue & Cell 44
(2): 80-86.
April 2012
Transcriptional expression profile of cultured human embryonic stem cells in vitro and in vivo.
Keil, M., Siegert, A., Eckert, K., Gerlach, J., Haider, W. and Fichtner, I.
In Vitro Cellular & Developmental Biology Animal 48
(3): 165-174.
March 2012
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells.
Sack, U., Walther, W., Scudiero, D., Selby, M., Aumann, J., Lemos, C., Fichtner, I., Schlag, P.M., Shoemaker, R.H. and Stein, U.
Molecular Biology of the Cell 22
(18): 3344-3354.
September 2011
Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer.
Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., Fichtner, I., Schlag, P.M., Shoemaker, R.H. and Stein, U.
Journal of the National Cancer Institute 103
(13): 1018-1036.
6 July 2011
Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk, J., Rolff, J., Dorn, C., Leschber, G. and Fichtner, I.
European Journal of Cardio-Thoracic Surgery 40
(1): e29-e33.
July 2011
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Bergman, A.M., Adema, A.D., Balzarini, J., Bruheim, S., Fichtner, I., Noordhuis, P., Fodstad, O., Myhren, F., Sandvold, M.L., Hendriks, H.R. and Peters, G.J.
Investigational New Drugs 29
(3): 456-466.
June 2011
Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.
Bachmeier, B., Fichtner, I., Killian, P.H., Kronski, E., Pfeffer, U. and Efferth, T.
PLoS ONE 6
(5): e20550.
26 May 2011
Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly (ethylene glycol) shell.
Calderon, M., Welker, P., Licha, K., Fichtner, I., Graeser, R., Haag, R. and Kratz, F.
Journal of Controlled Release 151
(3): 295-301.
10 May 2011
The antiangiogenic and antitumoral activity of titanocene Y* in vivo.
Fichtner, I., Behrens, D., Claffey, J., Deally, A., Gleeson, B., Patil, S., Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 8
(4): 302-307.
May 2011
Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
Winsel, S., Sommer, A., Eschenbrenner, J., Mittelstaedt, K., Klar, U., Hammer, S. and Hoffmann, J.
PLoS ONE 6
(4): e19273.
29 April 2011
Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.
Bijnsdorp, I.V., Schwendener, R.A., Schott, H., Fichtner, I., Smid, K., Laan, A.C., Schott, S., Losekoot, N., Honeywell, R.J. and Peters, G.J.
Investigational New Drugs 29
(2): 248-257.
April 2011
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
Tan, W.L., Bhattacharya, B., Loh, M., Balasubramanian, I., Akram, M., Dong, D., Wong, L., Thakkar, B., Salto-Tellez, M., Soo, R.A., Fichtner, I., Iacopetta, B. and Soong, R.
Cancer Biology & Therapy 11
(6): 599-608.
15 March 2011
Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.
Stein, U., Arlt, F., Smith, J., Sack, U., Herrmann, P., Walther, W., Lemm, M., Fichtner, I., Shoemaker, R.H. and Schlag, P.M.
Neoplasia 13
(2): 131-144.
February 2011
Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.
Wulf-Goldenberg, A., Eckert, K. and Fichtner, I.
Cytotherapy 13
(1): 108-113.
January 2011
Activation of the CMV-IE promoter by hyperthermia in vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expression.
Kobelt, D., Aumann, J., Fichtner, I., Stein, U., Schlag, P.M. and Walther, W.
Molecular Biotechnology 46
(2): 197-205.
October 2010
Interwoven four-compartment capillary membrane technology for three-dimensional perfusion with decentralized mass exchange to scale up embryonic stem cell culture.
Gerlach, J., Luebberstedt, M., Edsbagge, J., Ring, A., Hout, M., Baun, M., Rossberg, I., Knoespel, F., Peters, G., Eckert, K., Wulf-Goldenberg, A., Bjoerquist, P., Stachelscheid, H., Urbaniak, T., Schatten, G., Miki, T., Schmelzer, E. and Zeilinger, K.
Cells Tissues Organs 192
(1): 39-49.
June 2010
Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Brueckner, B., Rius, M., Rivera Markelova, M., Fichtner, I., Hals, P.A., Sandvold, M.L. and Lyko, F.
Molecular Cancer Therapeutics 9
(5): 1256-1264.
May 2010
Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model.
Orthmann, A., Zeisig, R., Koklic, T., Sentjurc, M., Wiesner, B., Lemm, M. and Fichtner, I.
Journal of Pharmaceutical Sciences 99
(5): 2423-2433.
May 2010
Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
Wenzel, J., Zeisig, R., Haider, W., Habedank, S. and Fichtner, I.
Breast Cancer Research and Treatment 121
(1): 13-22.
May 2010
Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted CAKI-1 tumors in mice.
Fichtner, I., Claffey, J., Deally, A., Gleeson, B., Hogan, M., Rivera Markelova, M., Mueller-Bunz, H., Weber, H. and Tacke, M.
Journal of Organometallic Chemistry 695
(8): 1175-1181.
15 April 2010
Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice.
Deak, E., Ruester, B., Keller, L., Eckert, K., Fichtner, I., Seifried, E. and Henschler, R.
Cytotherapy 12
(2): 260-264.
April 2010
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer, S., Sommer, A., Fichtner, I., Becker, M., Rolff, J., Merk, J., Klar, U. and Hoffmann, J.
Clinical Cancer Research 16
(5): 1452-1465.
1 March 2010
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Graeser, R., Esser, N., Unger, H., Fichtner, I., Zhu, A., Unger, C. and Kratz, F.
Investigational New Drugs 28
(1): 14-19.
February 2010
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Adema, A.D., Laan, A.C., Myhren, F., Fichtner, I., Verheul, H.M., Sandvold, M.L. and Peters, G.J.
International Journal of Oncology 36
(1): 285-294.
1 January 2010
Comparison of the effect of orally administered soluble β-(1-3),(1-6)-D-glucan and of G-CSF on the recovery of murine hematopoiesis.
Harnack, U., Eckert, K., Fichtner, I. and Pecher, G.
In Vivo 24
(1): 59-63.
January 2010
Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.
Wenzel, J., Zeisig, R. and Fichtner, I.
Clinical and Experimental Metastasis 27
(1): 25-34.
January 2010
Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.
Bracker, T.U., Sommer, A., Fichtner, I., Faus, H., Haendler, B. and Hess-Stumpp, H.
International Journal of Oncology 35
(4): 909-920.
October 2009
Oral administration of a soluble 1-3, 1-6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice.
Harnack, U., Eckert, K., Fichtner, I. and Pecher, G.
International Immunopharmacology 9
(11): 1298-1303.
October 2009
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Merk, J., Rolff, J., Becker, M., Leschber, G. and Fichtner, I.
European Journal of Cardio-Thoracic Surgery 36
(3): 454-459.
September 2009
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann, J., Morkel, M., Besser, D., Budczies, J., Kosel, F., Brembeck, F.H., Stein, U., Fichtner, I., Schlag, P.M. and Birchmeier, W.
Gastroenterology 137
(11): 165-175.
July 2009
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj, K., Graeser, R., Fichtner, I. and Kratz, F.
Cancer Chemotherapy and Pharmacology 64
(2): 413-418.
July 2009
Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo.
Heringer-Walther, S., Eckert, K., Schumacher, S.M., Uharek, L., Wulf-Goldenberg, A., Gembardt, F., Fichtner, I., Schultheiss, H.P., Rodgers, K. and Walther, T.
Haematologica 94
(6): 857-860.
June 2009
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Hoffmann, J., Fichtner, I., Lemm, M., Lienau, P., Hess-Stumpp, H., Rotgeri, A., Hofmann, B. and Klar, U.
Neuro Oncology 11
(2): 158-166.
April 2009
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Wenzel, J., Zeisig, R. and Fichtner, I.
International Journal of Pharmaceutics 370
(1-2): 121-128.
31 March 2009
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
Diaz Miqueli, A., Rolff, J., Lemm, M., Fichtner, I., Perez, R. and Montero, E.
British Journal of Cancer 100
(6): 950-958.
24 March 2009
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.
Stein, U., Walther, W., Arlt, F., Schwabe, H., Smith, J., Fichtner, I., Birchmeier, W. and Schlag, P.M.
Nature Medicine 15
(1): 59-67.
January 2009
Anti-proliferative efficacy of icariin on HepG2 hepatoma and its possible mechanism of action.
Yang, J.X., Fichtner, I., Becker, M., Lemm, M. and Wang, X.M.
American Journal of Chinese Medicine 37
(6): 1153-1165.
2009
Nonviral jet-injection technology for intratumoral in vivo gene transfer of naked DNA.
Walther, W., Fichtner, I., Schlag, P.M. and Stein, U.S.
Methods in Molecular Biology 542
: 195-208.
2009
Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers.
Rolff, J., Dorn, C., Merk, J. and Fichtner, I.
Journal of Oncology 2009
: 814140.
2009
Antitumor activity of oxali-titanocene Y in xenografted CAKI-1 tumors in mice.
Fichtner, I., Behrens, D., Claffey, J., Gleeson, B., Hogan, M., Wallis, D., Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 5
(8): 489-493.
December 2008
Interaction of alkylphospholipid liposomes with MT-3 breast-cancer cells depends critically on cholesterol concentration.
Koklic, T., Zeisig, R. and Sentjurc, M.
Biochimica et Biophysica Acta - Biomembranes 1778
(12): 2682-2689.
December 2008
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M. and Merk, J.
Clinical Cancer Research 14
(20): 6456-6468.
15 October 2008
In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine.
Bijnsdorp, I., Schwendener, R., Schott, H., Schott, S., Fichtner, I., Honeywell, R., Losekoot, N., Laan, A. and Peters, G.J.
Nucleic Acids Symposium Series 52
: 651.
8 September 2008
In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa, C., Mann-Steinberg, H., Fichtner, I., Weber, H., Satchi-Fainaro, R., Biniossek, M.L. and Kratz, F.
Bioconjugate Chemistry 19
(7): 1414-1422.
July 2008
Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis.
Goldin-Lang, P., Tran, Q.V., Fichtner, I., Eisenreich, A., Antoniak, S., Schulze, K., Coupland, S.E., Poller, W., Schultheiss, H.P. and Rauch, U.
Oncology Reports 20
(1): 123-128.
July 2008
Praeklinische Daten als Grundlage fuer die Konzeption klinischer Studien [Preclinical data as basis for the design of clinical studies].
Fichtner, I.
Onkologie 31
(Suppl. 2): 34-38.
May 2008
Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice.
Dowling, C.M., Claffey, J., Cuffe, S., Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K., Watson, R.W. and Tacke, M.
Letters in Drug Design & Discovery 5
(2): 141-144.
March 2008
Cytokine-pretreatment of CD34(+) cord blood stem cells in vitro reduces long-term cell engraftment in NOD/SCID mice.
Wulf-Goldenberg, A., Eckert, K. and Fichtner, I.
European Journal of Cell Biology 87
(2): 69-80.
14 February 2008
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.
Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I. and Lage, H.
Molecular Therapy 16
(1): 178-186.
January 2008
In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine.
Bijnsdorp, I.V., Schwendener, R.A., Schott, H., Fichtner, I., Smid, K., Schott, S., Laan, A.C. and Peters, G.J.
Nucleosides Nucleotides & Nucleic Acids 26
(10-12): 1619-1624.
5 December 2007
Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo.
Bannon, J.H., Fichtner, I., O'Neill, A., Pampillon, C., Sweeney, N.J., Strohfeldt, K., Watson, R.W., Tacke, M. and McGee, M.M.
British Journal of Cancer 97
(9): 1234-1241.
5 November 2007
Development of albumin-binding camptothecin prodrugs using a peptide positional scanning library.
Schmid, B., Warnecke, A., Fichtner, I., Jung, M. and Kratz, F.
Bioconjugate Chemistry 18
(6): 1786-1799.
November 2007
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Yde, C.W., Frogne, T., Lykkesfeldt, A.E., Fichtner, I., Issinger, O.G. and Stenvang, J.
Cancer Letters 256
(2): 229-237.
28 October 2007
Enhanced tumorigenicity of fibroblasts transformed with human herpesvirus 8 chemokine receptor vGPCR by successive passage in nude and immunocompetent mice.
Thirunarayanan, N., Cifire, F., Fichtner, I., Posner, S., Benga, J., Reiterer, P., Kremmer, E., Koelble, K. and Lipp, M.
Oncogene 26
(39): 5702-5712.
23 August 2007
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells.
Behrens, D., Gill, J.H. and Fichtner, I.
Molecular and Cellular Endocrinology 274
(1-2): 19-29.
15 August 2007
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke, A., Fichtner, I., Sass, G. and Kratz, F.
Archiv der Pharmazie 340
(8): 389-395.
August 2007
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts.
Behrens, D., Lykkesfeldt, A.E. and Fichtner, I.
Targeted Oncology 2
(3): 135-144.
July 2007
Albumin-Binding Prodrugs of Camptothecin and Doxorubicin with an Ala-Leu-Ala-Leu-Linker That Are Cleaved by Cathepsin B: Synthesis and Antitumor Efficacy.
Schmid, B., Chung, D.E., Warnecke, A., Fichtner, I. and Kratz, F.
Bioconjugate Chemistry 18
(3): 702-716.
May 2007
Poly(ethylene oxide)-block-poly(glutamic acid) coated maghemite nanoparticles: in vitro characterization and in vivo behaviour.
Kaufner, L., Cartier, R., Wuestneck, R., Fichtner, I., Pietschmann, S., Bruhn, H., Schuett, D., Thuenemann, A.F. and Pison, U.
Nanotechnology 18
(11): 115710.
21 March 2007
Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice.
Zeisig, R., Koklic, T., Wiesner, B., Fichtner, I. and Sentjurc, M.
Archives of Biochemistry and Biophysics 459
(1): 98-106.
1 March 2007
Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression.
Walther, W., Arlt, F., Fichtner, I., Aumann, J., Stein, U. and Schlag, P.M.
Molecular Cancer Therapeutics 6
(1): 236-243.
January 2007
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Shalapour, S., Zelmer, A., Pfau, M., Moderegger, E., Costa-Blechschmidt, C., van Landeghem, F.K., Taube, T., Fichtner, I., Buehrer, C., Henze, G., Seeger, K. and Wellmann, S.
Clinical Cancer Research 12
(18): 5526-5532.
15 September 2006
Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer, J.M., Fichtner, I., Baeuerle, P.A. and Kufer, P.
Journal of Immunotherapy 29
(5): 477-488.
September 2006
Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Einsiedel, H.G., Kawan, L., Eckert, C., Witt, O., Fichtner, I., Henze, G. and Seeger, K.
Leukemia 20
(8): 1435-1436.
August 2006
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., Silva, A.D., Locher, M., Kischel, R., Lutterbuese, R., Kufer, P. and Baeuerle, P.A.
Cancer Immunology Immunotherapy 55
: 785-796.
July 2006
Uptake, biodistribution, and time course of naked plasmid DNA trafficking after intratumoral in vivo jet injection.
Walther, W., Minow, T., Martin, R., Fichtner, I., Schlag, P.M. and Stein, U.
Human Gene Therapy 17
(6): 611-624.
15 June 2006
Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K. and Tacke, M.
Anti-Cancer Drugs 17
(3): 333-336.
March 2006
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., Kleindienst, P., Wimberger, P., Kimmig, R., Fichtner, I., Kufer, P., Hofmeister, R., da Silva, A.J. and Baeuerle, P.A.
Molecular Immunology 43
(8): 1129-1143.
March 2006
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H.W. and Cinatl, J.
International Journal of Oncology 28
(2): 439-446.
February 2006
Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance.
Besada, V., Diaz, M., Becker, M., Ramos, Y., Castellanos-Serra, L. and Fichtner, I.
Proteomics 6
(3): 1038-1048.
February 2006
Membrane switch hypothesis. 1. Cell density influences lateral domain structure of tumor cell membranes.
Koklic, T., Pirs, M., Zeisig, R., Abramovic, Z. and Sentjurc, M.
Journal of Chemical Information and Modeling 45
(6): 1701-1707.
28 November 2005
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C. and Drevs, J.
Archiv der Pharmazie 338
: 462-472.
7 October 2005
Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs.
Mravljak, J., Zeisig, R. and Pecar, S.
Journal of Medicinal Chemistry 48
(20): 6393-6399.
6 October 2005
Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma.
Walther, W., Stein, U., Fichtner, I., Kobelt, D., Aumann, J., Arlt, F. and Schlag, P.M.
Molecular Therapy 12
(6): 1176-1184.
29 September 2005
Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver.
Sharma, A.D., Cantz, T., Richter, R., Eckert, K., Henschler, R., Wilkens, L., Jochheim-Richter, A., Arseniev, L. and Ott, M.
American Journal of Pathology 167
(2): 555-564.
1 August 2005
Effect of surface modified liposomes on the aggregation of platelets and tumor cells.
Keil, C., Zeisig, R. and Fichtner, I.
Thrombosis and Haemostasis 94
(2): 404-411.
August 2005
The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
Carstanjen, D., Gross, A., Kosova, N., Fichtner, I. and Salama, A.
Transfusion 45
: 1192-1200.
1 July 2005
Quinols as novel therapeutic agents. 2.(1) 4-(1-arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.
Berry, J.M., Bradshaw, T.D., Fichtner, I., Ren, R., Schwalbe, C.H., Wells, G., Chew, E.H., Stevens, M.F. and Westwell, A.D.
Journal of Medicinal Chemistry 48
: 639-644.
27 January 2005
Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.
Becker, M., Sommer, A., Kraetzschmar, J.R., Seidel, H., Pohlenz, H.D. and Fichtner, I.
Molecular Cancer Therapeutics 4
: 151-170.
1 January 2005
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbuese, R., Junghahn, I., Kasimir-Bauer, S., Wimberger, P., Kimmig, R. and Baeuerle, P.A.
Cancer Research 65
: 2882-2889.
1 January 2005
Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers.
Henschler, R., Goettig, S., Junghahn, I., Bug, G., Seifried, E., Mueller, A.M. and Fichtner, I.
Leukemia Research 29
(10): 1191-1199.
1 January 2005
Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved non-viral intratumoral in vivo gene transfer by jet-injection.
Walther, W., Stein, U., Siegel, R., Fichtner, I. and Schlag, P.M.
Journal of Gene Medicine 7
(4): 477-485.
1 January 2005
Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug Carboplatin designed as albumin-binding prodrugs.
Warnecke, A., Fichtner, I., Garmann, D., Jaehde, U. and Kratz, F.
Bioconjugate Chemistry 15
(6): 1349-1359.
1 November 2004
Differential protein expression pattern in tamoxifen-sensitive and -resistant breast cancer xenografts.
Fichtner, I., Becker, M., Besada, V. and Castellanos-Serra, L.
International Journal of Clinical Pharmacology and Therapeutics 42
(11): 632-634.
November 2004
The experimental antitumor agents phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.
Fichtner, I., Monks, A., Hose, C., Stevens, M.F. and Bradshaw, T.D.
Breast Cancer Research and Treatment 87
(1): 97-107.
1 September 2004
Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo.
Zeisig, R., Rueckerl, D. and Fichtner, I.
Anti-Cancer Drugs 15
(7): 707-714.
1 August 2004
In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.
Fichtner, I., Becker, M., Zeisig, R. and Sommer, A.
European Journal of Cancer 40
(6): 845-851.
April 2004
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou, A., Iakovou, K., Gikas, E., Fichtner, I., Fiebig, H.H., Kelland, L.R., Double, J.A., Bibby, M.C. and Hendriks, H.R.
Anticancer Research 24
(2): 907-919.
March 2004
Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro.
Zeisig, R., Stahn, R., Wenzel, K., Behrens, D. and Fichtner, I.
Biochimica et Biophysica Acta - Biomembranes 1660
(1): 31-40.
28 January 2004
Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro.
Zeisig, R., Teppke, A.D., Behrens, D. and Fichtner, I.
Breast Cancer Research and Treatment 87
(3): 245-254.
1 January 2004
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.
Fichtner, I., Slisow, W., Gill, J., Becker, M., Elbe, B., Hillebrand, T. and Bibby, M.
European Journal of Cancer 40
(2): 298-307.
January 2004
Animal experiments - An essential component for the development of liposomal anticancer agents.
Fichtner, I., Reszka, R., Arndt, D. and Zeisig, R.
Journal of Liposome Research 13
(1): 9-15.
3 December 2003
A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour, A.M., Drevs, J., Esser, N., Hamada, F.M., Badary, O.A., Unger, C., Fichtner, I. and Kratz, F.
Cancer Research 63
(14): 4062-4066.
15 July 2003
CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity.
Erben, U., Thiel, E., Bittroff-Leben, A., Schoch, C., Fichtner, I., Durkop, H. and Notter, M.
International Journal of Cancer 105
(2): 232-240.
10 June 2003
Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias-correlation to the expression of multidrug resistance proteins.
Fichtner, I., Paal, K., Borgmann, A., Badiali, L., Wurm, R. and Henze, G.
Anticancer Research 23
(3): 2657-2664.
May 2003
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct1.
Dreier, T., Baeuerle, P.A., Fichtner, I., Gruen, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbuese, R., Riethmueller, G., Gjorstrup, P. and Bargou, R.C.
Journal of Immunology 170
(8): 4397-4402.
15 April 2003
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Fichtner, I., Becker, M. and Baumgart, J.
European Journal of Cancer 39
(6): 801-807.
April 2003
Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy.
Zeisig, R., Ress, A., Fichtner, I. and Walther, W.
Cancer Gene Therapy 10
(4): 302-311.
April 2003
Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice.
Nitsche, A., Junghahn, I., Thulke, S., Aumann, J., Radonic, A., Fichtner, I. and Siegert, W.
Stem Cells 21
(2): 236-244.
March 2003
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drueckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderling, C., Folkers, G., Fichtner, I. and Unger, C.
Journal of Medicinal Chemistry 45
(25): 5523-5533.
5 December 2002
Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems.
Becker, M., Nitsche, A., Neumann, C., Aumann, J., Junghahn, I. and Fichtner, I.
British Journal of Cancer 87
(11): 1328-1335.
18 November 2002
The influence of cholesterol and charge on the membrane domains of alkylphospholipid liposomes as studied by EPR.
Koklic, T., Sentjurc, M. and Zeisig, R.
Journal of Liposome Research 12
(4): 335-352.
November 2002
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf, S., Preithner, S., Mayer, P., Lippold, S., Wolf, A., Hanakam, F., Fichtner, I., Kufer, P., Raum, T., Riethmueller, G., Baeuerle, P.A. and Dreier, T.
International Journal of Cancer 100
(1): 101-110.
1 July 2002
Intratumoral low-volume jet-injection for efficient nonviral gene transfer.
Walther, W., Stein, U., Fichtner, I., Voss, C., Schmidt, T., Schleef, M., Nellessen, T. and Schlag, P.M.
Molecular Biotechnology 21
(2): 105-115.
1 June 2002
The EORTC laboratory research division.
Brunner, N., Double, J., Fichtner, I., Gescher, A., Newell, D., Oosterhuis, W. and Price, P.
European Journal of Cancer 38
(4): S14-S18.
March 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw, T.D., Bibby, M.C., Double, J.A., Fichtner, I., Cooper, P.A., Alley, M.C., Donohue, S., Stinson, S.F., Tomaszewjski, J.E., Sausville, E.A. and Stevens, M.F.G.
Molecular Cancer Therapeutics 1
(4): 239-246.
1 February 2002
Human hematopoiesis in murine embryos after injecting human cord blood-derived hematopoietic stem cells into murine blastocysts.
Harder, F., Henschler, R., Junghahn, I., Lamers, M.C. and Mueller, A.M.
Blood 99
(2): 719-721.
15 January 2002
Inhibition of carbohydrate mediated cell adhesion by liposomes as a possible way to prevent tumour metastasis.
Zeisig, R., Stahn, R. and Fichtner, I.
Cellular and Molecular Biology Letters 7
(2): 270-271.
2002
Altered neutrophil homeostasis in kinin B1 receptor deficient mice.
Araújo, R.C., Kettritz, R., Fichtner, I., Paiva, A.C.M., Pesquero, J.B. and Bader, M.
Biological Chemistry 382
: 91-95.
1 January 2001
Analysis of mouse beta-haptoglobin chain by lectin affinoblotting detection.
Roemer, I., Vogel, T., Otto, A., Fichtner, I. and Klose, J.
Electrophoresis 22
: 3038-3042.
1 January 2001
Cancerostatic octadecylpiperidinoylphosphate liposomes: effect of composition on uptake by and toxicity to J774 mouse macrophage cells and MT1 breast cancer cells in vitro.
Zeisig, R., Stahn, R., Teppke, A.D. and Arndt, D.
Anti-Cancer Drug Design 16
(1): 19-26.
1 January 2001
Early macrophage and cytokine response during the growth of immunogenic and non-immunogenic murine tumors.
Kisseleva, E., Becker, M., Lemm, M. and Fichtner, I.
Anticancer Research 21
(5): 3477-3484.
1 January 2001
Generation of an immortalized human CD4+ T cell clone inhibiting tumor growth in mice.
Pecher, G., Harnack, U., Guenther, M., Hummel, M., Fichtner, I. and Schenk, J.A.
Biochemical and Biophysical Research Communications 283
(4): 738-742.
1 January 2001
In vivo Gentransfer nackter DNA in xenotransplantierte Kolonkarzinome in der Nude Maus mit Hilfe der Jet-Injektion [In vivo gene transfer of naked DNA into xenotransplanted colon carcinoma by jet-injection].
Walther, W., Stein, U., Fichtner, I. and Schlag, P.M.
Chirurgisches Forum 30
: 69-72.
1 January 2001
Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models.
Lode, J., Fichtner, I., Kreuter, J., Berndt, A., Diederichs, J.E. and Reszka, R.
Pharmaceutical Research 18
(11): 1613-1619.
1 January 2001
Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice.
Arndt, D., Zeisig, R., Bechtel, D. and Fichtner, I.
Drug Delivery 8
: 1-7.
1 January 2001
Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology.
Walther, W., Stein, U., Fichtner, I., Malcherek, L., Lemm, M. and Schlag, P.M.
Gene Therapy 8
(3): 173-180.
1 January 2001
Preclinical and clinical aspects on the use of amifostine as chemoprotectorin neuroblastoma patients.
Fulda, S., Fichtner, I., Hero, B. and Berthold, F.
Medical and Pediatric Oncology 36
: 199-202.
1 January 2001
Quantification of human cells in NOD/SCID mice by duplex real-time polymerase reaction.
Nitsche, A., Becker, M., Junghahn, I., Aumann, J., Landt, O., Fichtner, I., Wittig, B. and Siegert, W.
Haematologica 86
: 693-699.
1 January 2001
Sialyl Lewisx-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells.
Stahn, R., Grittner, C., Zeisig, R., Karsten, U., Felix, S.B. and Wenzel, K.
Cellular and Molecular Life Sciences 58
(1): 141-147.
1 January 2001
The composition-dependent presence of free (micellar) alkylphospholipid in liposomal formulations of octadecyl-1,1-dimethyl-piperidino-4-yl-phosphate affects its cytotoxic activity in vitro.
Zeisig, R., Mueller, K., Maurer, N., Arndt, D. and Fahr, A.
Journal of Membrane Biology 182
(1): 61-69.
1 January 2001
Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.
Borgmann, A., Baldy, C., von Stackelberg, A., Beyermann, B., Fichtner, I., Nuernberg, P. and Henze, G.
Pediatric Hematology and Oncology 17
(8): 635-650.
1 December 2000
Donor stromal cells from human blood engraft in NOD/SCID mice.
Goan, S.R., Junghahn, I., Wissler, M., Becker, M., Aumann, J., Just, U., Martiny-Baron, G., Fichtner, I. and Henschler, R.
Blood 96
: 3971-3978.
1 December 2000
Phospholipid- and fatty acid-composition in the erythrocyte membrane of the one-humped camel [Camelus dromedarius] and its influence on vesicle properties prepared from these lipids.
Warda, M. and Zeisig, R.
Deutsche Tieraerztliche Wochenschrift 107
(9): 368-373.
1 September 2000
Development and characterization of a tamoxifen resistant breast carcinoma xenograft.
Naundorf, H., Becker, M., Lykkesfeldt, A.E., Elbe, B., Neumann, C., Buttner, B. and Fichtner, I.
British Journal of Cancer 82
(11): 1844-1850.
1 June 2000
mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors.
Walther, W., Stein, U., Fichtner, I., Alexander, M., Shoemaker, R.H. and Schlag, P.M.
Cancer Gene Therapy 7
(6): 893-900.
1 June 2000
Cell adhesion inhibition by glycoliposomes: Effects of vesicle diameter and ligand density.
Stahn, R. and Zeisig, R.
Tumor Biology 21
(3): 176-186.
1 May 2000
Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf, H., Jost-Reuhl, B., Becker, M., Reuhl, T., Neumann, C. and Fichtner, I.
Breast Cancer Research and Treatment 60
(1): 81-92.
1 March 2000
Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5' -> 5')-N4-octadecyl-1-beta-d-arabinofuranosylcytosine.
Horber, D.H., Cattaneo-Pangrazzi, R.M.C., von Ballmoos, P., Schott, H., Ludwig, P.S., Eriksson, S., Fichtner, I. and Schwendener, R.A.
Journal of Cancer Research and Clinical Oncology 126
(6): 311-319.
1 January 2000
In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model.
Kratz, F., Roth, T., Fichtner, I., Schumacher, P., Fiebig, H.H. and Unger, C.
Journal of Drug Targeting 8
: 305-318.
1 January 2000
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Arndt, D., Zeisig, R., Fichtner, I., Teppke, A.D. and Fahr, A.
Breast Cancer Research and Treatment 58
(1): 71-80.
November 1999
Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann, J., Schmidt-Peter, P., Haensch, W., Naundorf, H., Bunge, A., Becker, M. and Fichtner, I.
Clinical Cancer Research 5
: 2198-2204.
1 August 1999
Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-) hormones.
Dehmel, A., Becker, M., Lemm, M. and Fichtner, I.
Anticancer Research 19
: 1977-1987.
1 May 1999
Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Mobest, D., Goan, S.R., Junghahn, I., Winkler, J., Fichtner, I., Hermann, V., Becker, M., de Lima-Hahn, E. and Henschler, R.
Stem Cells 17
: 152-161.
1 January 1999
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.
Mrowietz, U., Schwenk, U., Maune, S., Bartels, J., Kuepper, M., Fichtner, I., Schroeder, J.M. and Schadendorf, D.
British Journal of Cancer 79
: 1025-1031.
1 January 1999
Alkylphospholipid liposomes: Preparation, properties and use in cancer research.
Arndt, D., Zeisig, R. and Fichtner, I.
Drugs of Today 34 Suppl. F
: 83-96.
1 December 1998
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Zeisig, R., Arndt, D., Stahn, R. and Fichtner, I.
Biochimica et Biophysica Acta - Biomembranes 1414
(1-2): 238-248.
11 November 1998
1-beta-D-Arabinofuranosylcytosine-5'-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C.
Brachwitz, H., Bergmann, J., Fichtner, I., Thomas, Y., Vollgraf, C., Langen, P. and Berdel, W.E.
Journal of Lipid Research 39
: 162-172.
1 January 1998
In vivo evaluation of a cytostatic drug-inducible vector for the expression of TNF-alpha.
Walther, W., Stein, U., Fichtner, I., Shoemaker, R.H., Alexander, M. and Schlag, P.M.
Proceedings of the American Association of Cancer Research 39
: 520.
1 January 1998
In vivo evaluation of a drug-inducible vector system for the combined gene- and chemotherapy of cancer.
Walther, W., Stein, U., Fichtner, I., Naundorf, H., Alexander, M., Shoemaker, R.H. and Schlag, P.M.
Advances in Experimental Medicine and Biology 451
: 139-144.
1 January 1998
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
Arndt, D., Zeisig, R., Eue, I., Sternberg, B. and Fichtner, I.
Breast Cancer Research and Treatment 43
: 237-246.
1 January 1997
Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
Reszka, R., Beck, P., Fichtner, I., Hentschel, M., Richter, J. and Kreuter, J.
Journal of Pharmacology and Experimental Therapeutics 280
: 232-237.
1 January 1997
Bromelain proteases suppress growth, invasion and lung metastasis of B16F10 mouse melanoma cells.
Grabowska, E., Eckert, K., Fichtner, I., Schulze-Forster, K. and Maurer, H.R.
International Journal of Oncology 11
: 243-248.
1 January 1997
Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein, U., Walther, W., Lemm, M., Naundorf, H. and Fichtner, I.
International Journal of Cancer 72
: 885-891.
1 January 1997
Development and characterization of novel multidrug resistant breast cancer lines.
Walther, W., Stein, U., Lemm, M., Naundorf, H. and Fichtner, I.
Proceedings of the American Association of Cancer Research 38
: 484.
1 January 1997
Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner, I., Lemm, M., Becker, M. and Berthold, F.
Anti-Cancer Drugs 8
: 174-181.
1 January 1997
Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner, I., Dehmel, A., Naundorf, H. and Finke, L.H.
Anticancer Research 17
: 3633-3646.
1 January 1997
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo.
Schadendorf, D., Kern, M.A., Artuc, M., Pahl, H.L., Rosenbach, T., Fichtner, I., Nuernberg, W., Stueting, S., von Stebut, E., Worm, M., Makki, A., Jurgovsky, K., Kolde, G. and Henz, B.M.
Journal of Cell Biology 135
(6 Pt 2): 1889-1898.
December 1996
Fibroblasts retrovirally transfected with the human IL-3 gene initiate and sustain multilineage human hematopoiesis in SCID mice: comparison of CD34-enriched vs CD34-enriched and in vitro expanded grafts.
Goan, S.R., Schwarz, K., von Harsdorf, S., von Schilling, C., Fichtner, I., Junghahn, I., Just, U. and Herrmann, F.
Bone Marrow Transplantation 18
: 513-519.
1 September 1996
Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo.
Shi, D.F., Bradshaw, T.D., Wrigley, S., McCall, C.J., Lelieveld, P., Fichtner, I. and Stevens, M.F.G.
Journal of Medicinal Chemistry 39
: 3375-3384.
1 January 1996
Detektion Mamma-Karzinom-spezifischer Proteine aus dem Serum xenotransplantierter Nacktmaeuse mittels differentieller zweidimensionaler Elektrophorese.
Vogel, T., Dehmel, A., Otto, A., Fichtner, I., Kaisers, H. and Schlag, P.M.
Langenbecks Archiv fuer Chirurgie Suppl.I
: 537-542.
1 January 1996
Drug-inducible vector for the conditional expression of the human TNFalpha gene.
Walther, W., Stein, U., Wendt, J. and Shoemaker, R.H.
Proceedings of the American Association of Cancer Research 37
: 350.
1 January 1996
Involvement of macrophages and cytokines into rejection mechanism of the drug-resistant and immunogenic murine lymphoma P388/adria.
Kisseleva, E., Becker, M., Lemm, M. and Fichtner, I.
Anticancer Research 16
: 1971-1978.
1 January 1996
MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas.
Stein, U., Shoemaker, R.H. and Schlag, P.M.
European Journal of Cancer 32 A
: 86-92.
1 January 1996
Metastatic potential of human melanoma cells in nude mice - characterisation of phenotype, cytokine secretion and tumour-associated antigens.
Schadendorf, D., Fichtner, I., Makki, A., Alijagic, S., Kuepper, M., Mrowietz, U. and Henz, B.M.
British Journal of Cancer 74
: 194-199.
1 January 1996
Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
Stein, U., Walther, W. and Shoemaker, H.
British Journal of Cancer 74
: 1384-1391.
1 January 1996
Preparation and properties of sterically stabilized hexadecylphosphochiline (miltefosine)-liposomes and influence of this modification on macrophage activation.
Zeisig, R., Eue, I., Kosch, M., Fichtner, I. and Arndt, D.
Biochimica et Biophysica Acta 1283
: 177-184.
1 January 1996
Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.
Naundorf, H., Parczyk, K., Zschiesche, W., Reinecke, S., Buettner, B., Saul, G.J., Sinn, B. and Fichtner, I.
Journal of Cancer Research and Clinical Oncology 122
: 14-20.
1 January 1996
Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein, U., Walther, W. and Shoemaker, R.H.
Journal of the National Cancer Institute 88
: 1383-1392.
1 January 1996
Vincristine induction of mutant and wild-type human multidrug-resitance promoters is cell- type-specific and dose-dependent.
Stein, U., Walther, W. and Shoemaker, R.H.
Journal of Cancer Research and Clinical Oncology 122
: 275-282.
1 January 1996
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis.
Goan, S.R., Fichtner, I., Just, U., Karawajew, L., Schultze, W., Krause, K.P., von Harsdorf, S., von Schilling, C. and Herrmann, F.
Blood 86
(1): 89-100.
1 July 1995
A comparative infrared spectroscopic study of human breast tumors and breast tumor cell xenografts.
Fabian, H., Jackson, M., Murphy, L., Watson, P.H., Fichtner, I. and Mantsch, H.H.
Biospectroscopy 1
: 37-45.
1 January 1995
Alkylphosphocholines and alkylphosphocholine liposomes.
Arndt, D., Zeisig, R., Eue, I. and Fichtner, I.
Journal of Liposome Research 5
: 91-98.
1 January 1995
Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulationof hematopoiesis.
Fichtner, I., Reszka, R., Goan, S.R. and Naundorf, H.
Medical Oncology 11
: 111-119.
1 January 1995
Gene transfer of human TNFalpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity.
Walther, W., Stein, U. and Pfeil, D.
International Journal of Cancer 61
(6): 832-839.
1 January 1995
Influence of liposomes rich in unsaturated or saturated fatty acids on the growth of human xenotransplanted mammary carcinomas and on the levels of heart type fatty acid binding protein.
Naundorf, H., Zschiesche, W., Reszka, R. and Fichtner, I.
In Vivo 9
: 247-252.
1 January 1995
Stimulation of hematopoiesis by carboplatin-liposomes.
Fichtner, I., Reszka, R., Becker, M., Lemm, M., Richter, J. and Rudolph, M.
Journal of Liposome Research 4
(1): 43-69.
March 1994
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro: use of liposomes.
Fichtner, I., Zeisig, R., Naundorf, H., Jungmann, S., Arndt, D., Asongwe, G., Double, J.A. and Bibby, M.C.
Breast Cancer Research and Treatment 32
: 269-279.
1 January 1994
Characterization of four drug resistant P388 sublines: resistance/sensitivity in vivo, resistance- and proliferation-markers, immunogenicity.
Fichtner, I., Stein, U., Hoffmann, J., Winterfeld, G., Pfeil, D. and Hentschel, M.
Anticancer Research 14
: 1995-2004.
1 January 1994
Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells.
Zeisig, R., Jungmann, S., Fichtner, I., Daemen, T. and Arndt, D.
Anticancer Research 14
: 1785-1790.
1 January 1994
Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro-growth.
Naundorf, H., Fichtner, I., Elbe, B., Saul, G.J., Haensch, W., Zschiesche, W. and Reinecke, S.
Breast Cancer Research and Treatment 32
: 187-196.
1 January 1994
Immunmodyfying properties of free and liposomal alkylphosphocholines.
Eue, I., Zeisig, R., Jungmann, S., Fichtner, I. and Arndt, D.
European Journal of Cell Biology 63
: 16-16.
1 January 1994
Influence of different promoters on the expression of tumor necrosis factor alpha in LS174T human colon carcinoma cells.
Uckert, W., Asche, O., Mahanty, B. and Fichtner, I.
International Journal of Oncology 5
: 865-871.
1 January 1994
Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state.
Pfeil, D., Bergmann, J., Fichtner, I., Stein, U., Hentschel, M., Rothe, I. and Goan, S.R.
Anticancer Research 14
: 571-576.
1 January 1994
Carboplatin - liposomes as activators of hematopoiesis.
Fichtner, I., Reszka, R., Schuett, M., Rudolph, M., Becker, M., Lemm, M., Richter, J. and Berger, I.
Oncology Research 5
: 65-74.
1 January 1993
Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice.
Naundorf, H., Fichtner, I., Saul, G.J., Haensch, W. and Buettner, B.
Journal of Cancer Research and Clinical Oncology 119
: 652-656.
1 January 1993
Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models.
Beck, P., Kreuter, J., Reszka, R. and Fichtner, I.
Journal of Microencapsulation 10
: 101-114.
1 January 1993
Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition.
Walther, W., Fichtner, I. and Uckert, W.
Anticancer Research 13
: 1565-1574.
1 January 1993
In vivo characterization of immunogenicity of a mitoxantrone-resistant murine P388 leukemia.
Fichtner, I., Reipert, B., Becker, M. and Lemm, M.
In Vivo 7
(1): 73-80.
January 1993
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo-testing of ether lipids and their derivatives.
Naundorf, H., Rewasowa, E.C., Fichtner, I., Buettner, B., Becker, M. and Goerlich, M.
Breast Cancer Research and Treatment 23
: 87-95.
1 January 1992
Establishment and characterization of a new human oestradiol- and progesteron-receptor-positive mammary carcinoma serially transplantable in nude mice.
Naundorf, H., Fichtner, I., Buettner, B. and Frege, J.
Journal of Cancer Research and Clinical Oncology 119
: 35-40.
1 January 1992
In vivo distribution and antitumor activity of liposomal 3',5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine.
van Borssum Waalkes, M., Fichtner, I., Dontjes, B., Lemm, M., Becker, M., Arndt, D. and Scherphof, G.L.
Journal of Microencapsulation 9
: 335-346.
1 January 1992
Investigations of droloxifene and other hormonal manipulations on N-nitrosomethylurea- induced rat mammary tumors. 2. Influence on estrogen receptor.
Goerlich, M., Winterfeld, G., Hauff, P., Arnold, W., Fichtner, I. and Staab, H.J.
Journal of Cancer Research and Clinical Oncology 119
: 97-100.
1 January 1992
Investigations of droloxifene and other hormone manipulations on N-nitrosomethylurea-induced rat mammary tumors. 1. Influence on tumor growth.
Winterfeld, G., Hauff, P., Goerlich, M., Arnold, W., Fichtner, I. and Staab, H.J.
Journal of Cancer Research and Clinical Oncology 119
: 91-96.
1 January 1992
Measurements of carbon clearance in mice as toxicity parameter for liposomal preparations.
Fichtner, I., Kniest, A. and Arndt, D.
In Vivo 6
: 113-118.
1 January 1992
Antitumor effects of alkylphosphocholines in different murine tumor models, use of liposomal preparations.
Zeisig, R., Fichtner, I., Arndt, D. and Jungmann, S.
Anti-Cancer Drugs 2
: 411-417.
1 January 1991
Messung der Bromsulfaleinretention der Maus als moeglicher Parameter zur Einschaetzung der Leberfunktion nach Gabe liposomaler Praeparationen.
Hoffmann, J., Fichtner, I., Becker, M. and Lemm, M.
Pharmazie 46
: 222-223.
1 January 1991
Pharmacokinetic behavior of 57CO-Bleomycin liposomes in mice: comparison with the unencapsulated substance.
Fichtner, I., Arndt, D., Reszka, R. and Gens, J.
Anti-Cancer Drugs 2
: 555-563.
1 January 1991
Stellenwert von Tierversuchen in der Onkologie. Moegliche Alternativen?
Fichtner, I.
Archiv fuer Geschwulstforschung 61
: 153-161.
1 January 1991
Tierexperimentelle Untersuchungen mit dem Immunsuppressivum Cyclosporin A (CSA) an syngenen Tumormodellen.
Ebert, A., Fichtner, I., Brandt, R. and Buettner, B.
Archiv fuer Geschwulstforschung 61
: 111-122.
1 January 1991
Book Section
Liposomes in the food industry.
Zeisig, R. and Caemmerer, B.
In:
Mircoencapsulation of Food Ingredients.
Leatherhead Publishing, Surrey, 101-119.
1 January 2001
Ex vivo expanded CD34+ blood progenitor cells display lymphomyeloid plus stromal cell differentiation potential after transplantation into NOD/SCID mice.
Goan, S.R., Junghahn, I., Fichtner, I., Becker, M., Just, U., Moebest, D. and Henschler, R.
In:
Relevance of Tumor Models for Anticancer Drug Development.
Contibutions to Oncology
.
Karger, Basel, 219-232.
1 January 1999
Transplantation of human haematopoietic or leukaemic cells into SCID and NOD/SCID mice.
Fichtner, I., Goan, S.R., Becker, M., Baldy, C., Borgmann, A., von Stackelberg, A. and Henze, H.
In:
Relevance of Tumor Models for Anticancer Drug Development.
Contibutions to Oncology
.
Karger, Basel, 207-217.
1 January 1999
IR-spectroscopy and IR-microscopy of human breast tumors, xenografted breast tumors, and breast tumor cell lines.
Fabian, H., Wessel, R., Jackson, M., Schwartz, A., Lasch, P., Fichtner, I., Mantsch, H.H. and Naumann, D.
In:
Infrared Spectroscopy: New Tool in Medicine. Proceedings of Infrared Spectroscopy: New Tool in Medicine : 28-30 January 1998, San Jose, California.
SPIE Proceedings Series ; 3257
.
SPIE, Bellingham, Wash., [s.p.].
1 January 1998
Encapsulation of the transition metal compounds Carboplatin (CP) and Lobaplatin (LP) in different types ofliposomes and their physico-chemical, biochemical and biological characterization.
Reszka, R., Fichtner, I., Goan, S.R., Rudolph, M. and Winter, R.
In:
Bioinorganic Chemistry - Transition Metals in Biology and their Coordination in Chemistry.
Wiley-VCH, Weinheim, 145-166.
1 January 1997
Effects of liposomes with defined fatty acid composition on xenotransplanted human mammary carcinomas.
Zschiesche, W., Naundorf, H., Reszka, R., Saul, G.J. and Fichtner, I.
In:
Immunodeficient Animals: Models for Cancer Research.
Contributions to Oncology ; 51, 51
.
Karger, Basel, 138-141.
1 January 1996
Establishment and characterization of human sarcoma lines transplanted into nude mice.
Hoffmann, J., Stein, U., Schmidt-Peter, P., Haensch, W., Naundorf, H., Scheper, R.J. and Fichtner, I.
In:
Immunodeficient Animals: Models for Cancer Research.
Contributions to Oncology ; 51
.
Karger, Basel, 57-60.
1 January 1996
Establishment and characterization of human xenotransplanted breast carcinoma lines: use for the screening of alkylphosphocholines (APC).
Fichtner, I., Naundorf, H., Saul, G.J., Zschiesche, W. and Zeisig, R.
In:
Immunodeficient Animals: Models for Cancer Research.
Contributions to Oncology ; 51, 51
.
Karger, Basel, 129-133.
1 January 1996
Influence of estradiol and tamoxifen on the growth and regulation of C-erbB-2, estradiol and progesterone receptors of mammary carcinoma 3366 transplanted into nude mice.
Naundorf, H., Zschiesche, W., Reineke, S., Saul, G.J., Frege, J., Buettner, B. and Fichtner, I.
In:
Immunodeficient Animals: Models for Cancer Research.
Contributions to Oncology ; 51, 51
.
Karger, Basel, 134-137.
1 January 1996
Peripheral blood stem cell-initiated human hematopoiesis in severe combined immunodeficient (SCID) mice is accelerated by a rat fibroblast cell line retrovirally transfected with the human IL-3 gene.
Goan, S.R., Fichtner, I., Just, J., Krause, K.P., Karawajew, L., Schwarz, K., von Harsdorf, R., von Schilling, C. and Herrmann, F.
In:
Immunodeficient Animals: Models of Cancer Research.
Contributions to Oncology ; 51
.
Karger, Basel, 171-175.
1 January 1996
Xenotransplantation of a novel hodgkin cell line HD-MyZ into SCID mice.
Bargou, R.C., Mapara, M.Y., Arnold, W., Daniel, P.T. and Doerken, B.
In:
Immunodeficient Animals: Models in Cancer Research.
Contributions to Oncology ; 51
.
Karger, Basel, 187-192.
1 January 1996
Macrophage mediated tumor toxicity of alkylphosphocholine liposomes.
Zeisig, R., Jungmann, S., Eue, I., Daemen, T., Fichtner, I., Nissen, E. and Arndt, D.
In:
Phospholipids: Characterization, Metabolism, and Novel Biological Applications : Proceedings of the 6th International Colloquium.
AOCS Press, Champaign, 126-133.
1 January 1995
Development and characterization of in vivo and in vitro tumor lines for investigation of the phenomenon of multidrug resistance in human sarcomas.
Hoffmann, J., Stein, U., Schmidt-Peter, P., Haensch, W., Naundorf, H. and Fichtner, I.
In:
Recent Advances in Chemotherapy. Proceedings of the 18th International Congress of Chemotherapy, Stockholm.
American Society for Microbiology, Washington, 885-887.
1 January 1994
Book
Immunodeficient Animals: Models for Cancer Research.
Arnold, W., Koepf-Maier, P. and Micheel, B.
Contributions to Oncology ; 51
.
Karger, Basel.
1 January 1996
Patent
Verfahren zur Diagnose und Therapie von antioestrogentherapieresistenten Brusttumoren [Diagnosis and therapy of breast tumours resistant to antiestrogen treatment].
Fichtner, I., Becker, M., Besada-Perez, V. and Castellanos-Serra, L.
DE10310198A1 ; WO0408137.
22 January 2004
Isolierung von Neuronen und Stammzellen fuer Nervenfasern aus einer Probe [Isolation of neurones and stem cells for nerve fibres from a sample].
Pfrieger, F.W. and Naegler, K.
EP1448764 ; WO0342374.
22 May 2003
Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol [Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel].
Reszka, R. and Fichtner, I.
DE10154464A1 ; DE10154464B4 ; EP1443904 ; WO0339437.
22 May 2003
Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen [Use of nucleosides, nucleobases and derivatives thereof for improved production of adult stem cells].
Langen, P. and Fichtner, I.
DE10117615A1 ; WO0281664.
10 October 2002
Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzuendlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen.
Stahn, R., Goletz, S., Jeschke, U., Fichtner, I. and Zeisig, R.
DE10056136A1.
16 May 2002
Mittel zur Tumortherapie auf Liposomenbasis, die Tamoxifen enthalten [Agents provided for treating tumors, based on liposomes, and containing tamoxifen].
Zeisig, R., Fichtner, I. and Arndt, D.
EP1135193.
31 October 2001
Mittel zum nichtviralen Transfer von DNS in eukaryotische Zellen.
Zeisig, R. and Walther, W.
DE19959690A1.
8 June 2000
Mittel zur Tumortherapie.
Zeisig, R., Fichtner, I. and Arndt, D.
DE19959689A1.
8 June 2000
Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika.
Fichtner, I. and Langen, P.
DE19842578A1 ; EP1037618.
23 March 2000
Carboplatin oder Lobaplatin enthaltende Zubereitungen zur Antitumortherapie und/oder Stimulierung des haematopoetischen Systems.
Reszka, R. and Fichtner, I.
EP0611303 ; US5,620,703.
2 July 1998
Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen toxischer Nebenwirkungen von Cytostatika.
Langen, P., Schuett, M., Koberling, A., Ihn, L. and Fichtner, I.
DE19652418A1.
10 June 1998
Verfahren zum Nachweis der Malignitaet okkulter Tumorzellen in Koerperfluessigkeiten.
Fichtner, I. and Nowak, C.
DE19640328A1 ; DE19640328C2.
12 March 1998
Verfahren zum Nachweis einer Hormon- bzw. Antihormonresistenz bei Tumoren [Method for detecting a hormone or antihormone resistance in cancers].
Naundorf, H., Fiebig, C., Neumann, C., Fichtner, I. and Becker, M.
DE19628298A1 ; DE19628298C2 ; EP0923739 ; US6,177,255.
15 January 1998
Verwendung von Carboplatin in lyotrophen Mesophasen zur Ueberwindung einer durch Zytostatika ausgeloesten Leukopenie.
Reszka, R. and Fichtner, I.
DE4134158C2.
13 February 1997
Liposomal verkapseltes Taxol, seine Herstellung und seine Verwendung.
Reszka, R., Brandl, M., Fichtner, I. and Warnke, G.
DE4430593A1 ; EP0776202A1 ; EP0776202B1 ; US6,090,955.
22 February 1996
Verfahren zur Herstellung von liposomal verkapseltem Taxol.
Reszka, R., Brandl, M., Fichtner, I. and Warnke, G.
DE4430593C2 ; DE4447770C2.
22 February 1996
Pharmazeutisches Mittel zur Tumortherapie.
Arndt, D., Zeisig, R. and Fichtner, I.
DE4408011C1.
2 November 1995
Neue Nukleosid-Lipid-Addukte, ihre Herstellung und ihre pharmazeutische Verwendung [Novel nucleoside-lipid addition compounds, their production and their pharmaceutical use].
Brachwitz, H., Langen, P., Fichtner, I., Berdel, W., Baeseler, M., Lachmann, U., Dressler, K. and Thomas, Y.
DE4400310A1 ; EP0738274 ; WO9518816.
13 July 1995
Review
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Huelsmann, H.J., Rolff, J., Bender, C., Jarahian, M., Korf, U., Herwig, R., Froehlich, H., Thomas, M., Merk, J., Fichtner, I., Sueltmann, H. and Kuner, R.
Lung Cancer 86
(2): 151-157.
November 2014
Improving the transport of chemotherapeutic drugs across the blood-brain barrier.
Orthmann, A., Fichtner, I. and Zeisig, R.
Expert Review of Clinical Pharmacology 4
(4): 477-490.
July 2011
Low-volume jet injection for efficient nonviral in vivo gene transfer.
Walther, W., Stein, U., Fichtner, I. and Schlag, P.M.
Molecular Biotechnology 28
(2): 121-128.
1 January 2004
Antineoplastic activity of alkylphosphocholines and alkylphosphochiline liposomes: A review of recent knowledge.
Arndt, D., Eue, I., Fichtner, I. and Zeisig, R.
1 January 1996
Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.
Walther, W. and Stein, U.
Journal of Molecular Medicine 74
: 379-392.
1 January 1996
Preparation and properties of alkylphospholipid liposomes: a review.
Zeisig, R., Fichtner, I. and Arndt, D.
Cellular and Molecular Biology Letters 1
: 447-457.
1 January 1996
Targeted vectors for gene therapy of cancer and retroviral infections.
Walther, W. and Stein, U.
Molecular Biotechnology 6
: 267-286.
1 January 1996
Pharmacological effects of carboplatin-liposomes (CPL) in mice: a review of present knowledge.
Fichtner, I., Reszka, R., Goan, S.R., Naundorf, H. and Hentschel, M.
Journal of Liposome Research 5
: 75-89.
1 January 1995
This list was generated on Wed Nov 13 16:44:26 2024 UTC.
![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
